To include your compound in the COVID-19 Resource Center, submit it here.

Metallic strategy

Why Viamet chose to stay private and spin out cancer assets

Viamet Pharmaceuticals Inc.'s decision to do a $60 million series D round one day after withdrawing its planned $75 million IPO late last month can be explained by a "choppy" IPO market and a strategic decision to form

Read the full 382 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers